Bay Area Cardiology physicians have been participating in clinical research since 1992. Since then we have been involved in over 90 studies both nationally and internationally. Through patient-oriented research Bay Area Cardiology seeks to improve treatments and outcomes.

 

Bay Area Cardiology is proud of its dedicated team of four full-time professionals who are experienced at coordinating trials and maintaining a high standard of quality and performance.

 

Our experience with clinical trials includes registries, investigational medications, FDA post-market approved drugs, coronary stents, peripheral stents, carotid stents, pacemakers, Bi-V, and AICD devices. Our participation is limited to only Phase III or Phase IV studies.

 

We participate in both office and hospital-based studies that cover a wide variety of cardiac and vascular medicine and treatments.

 

Our current enrolling studies include new diagnoses of Atrial Fibrillation, Pulmonary Arterial Hypertension, and Congestive Heart Failure.

 

The following are a few examples of clinical studies we have participated in:

 

ADAPTA (Medtronic) A randomized trial to compare single-chamber atrial (AAl) and Dual-chamber (DDD) pacing in patients with Sick Sinus Syndrome

 

– Ranked #1 out of 100 sites

 

– PI: Dr. Mester

 

RELY (Boehringer Ingelheim) Randomized Evaluation of Outcomes of Long Term Anticoagulant therapy.

 

– Ranked #9 out of 952 sites

– PI: Dr. Khant

 

RATE (St. Jude Medical) Registry of AT/AF Episodes in the CRM Device Population

 

– Ranked #5 out of 19 sites

 

– PI: Dr. Betzu

 

PREDETERMINE (NIHL) Markers of Sudden Cardiac Death Registry

 

– Ranked #6 out of 105 sites

 

– PI: Dr. Bugni

 

TRANSLATE (DCRI) TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome

 

– Ranked #55 out of 233

 

– PI: Dr. Rodriguez

 

IMPROVE-IT (Merck/Schering Plough) IMProved Reduction of Outcomes: Vytorin Efficacy International Trial

 

– Ranked #67 out of 359 sites

 

– PI: Dr. Betzu

 

CAMELLIA (Eisai) A Randomized, Double-blind, Placebo-controlled, Parallel- group Study to Evaluate the Long-term Treatment with BELVIQ (lorcaserin HCL) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors.

 

– Ranked #3 out of 400 sites

 

– PI: Dr. Chokshi

 

REVEAL (Merck/Oxford University) HPS 3/ TIMI 55: REVEAL (Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification): A large-scale, randomized placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease.

 

– Ranked #61 out of 151 sites

 

– PI: Dr. Khan

 

PAH (Actelion) Pulmonary Arterial Hypertension (PAH) Quality Enhancement Research Initiative (QuERI) Extension Program

 

– Ranked #22 out of 71 site

 

– PI: Dr. Dewhurst

 

ST SEGMENT (Medtronic) Virtuoso Implantable Cardioverter Defibrillator ST Segment Algorithm

 

– Ranked #4 out of 24 sites

 

– PI: Dr.Mester

 

1160.128 (Boehringer Ingelheim) A prospective, open-label study evaluating the efficacy of two management strategies (pantoprazole 40 mg q a.m. and taking Pradaxa with food (within 30 minutes after a meal)) on gastrointestinal symptoms (GIS) in patients newly on treatment with Pradaxa 150 mg b.i.d. or 75 mg b.i.d. for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF).

 

– Ranked #4 out of 26 sites

 

– PI: Dr. Khant

 

EFFECT-AF (Laser) An Atrial Fibrillation treatment registry

 

– Ranked #12 out of 54

 

– PI: Dr. Perzanowski